CD3Z genetic polymorphism in immune response to hepatitis B vaccination in two independent Chinese populations

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Pan, Li Ping ^a   Zhanz, Wei ^b   Zhang, Li ^c   Wu, Xiao Pan ^a   Zhu, Xi Lin ^a   Yan, Bing Yu ^c   Li, Jing Yun ^a   Xu, Ai Qiang ^c   Liu, Ying ^a   Li, Hui ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Shandong Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA; CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHINESE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VACCINATION; ACTIVE IMMUNIZATION; ASIAN; BODY MASS; CASE CONTROL STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETICS; GENOTYPE; IMMUNOLOGY; STATISTICAL MODEL;

ADULT; ANTIGENS, CD3; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNITY, ACTIVE; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANTIGEN, T-CELL; VACCINATION;

EID: 84859942972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035303     Document Type: Article

References (56)

1. Maddrey W, (2000) Hepatitis B: An important public health issue. J Med Virol 61: 362-366.
2. Zuckerman JN, Zuckerman AJ, (2000) Current topics in hepatitis B. J Infect 41: 130-136.
3. Lu FM, Zhuang H, (2009) Prevention of hepatitis B in China: achievements and challenges. Chin Med J (Engl) 122: 2925-2927.
4. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, et al. (1993) Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270: 2935-2939.
5. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM, (1985) Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254: 3187-3189.
6. Boland GJ, van Bommel T, Rulos-van den Berg A, van den Berg JP, van Loon AM, et al. (2003) The efficacy of a two-dose hepatitis B vaccination scheme. Adv Exp Med Biol 531: 185-190.
7. Hollinger FB, (1989) Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 87: 36S-40S.
8. Treadwell TL, Keeffe EB, Lake J, Read A, Friedman LS, et al. (1993) Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 95: 584-588.
9. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, et al. (2004) Genetic regulation of immune responses to vaccines in early life. Genes Immun 5: 122-129.
10. Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, et al. (2010) New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun 11: 232-238.
11. Godkin A, Davenport M, Hill AV, (2005) Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 41: 1383-1390.
12. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, et al. (2002) Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360: 991-995.
13. McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA, (1997) Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50: 8-14.
14. Png E, Thalamuthu A, Ong RT, Snippe H, Boland GJ, et al. (2011) A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet.
15. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, et al. (1988) Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. Jama 260: 1734-1738.
16. Yucesoy B, Sleijffers A, Kashon M, Garssen J, de Gruijl FR, et al. (2002) IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine 20: 3193-3196.
17. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, et al. (2004) HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39: 978-988.
18. Chen J, Liang Z, Lu F, Fang X, Liu S, et al. (2010) Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 29: 706-711.
19. Hohler T, Reuss E, Freitag CM, Schneider PM, (2005) A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology 42: 72-76.
20. Yucesoy B, Johnson VJ, Fluharty K, Kashon ML, Slaven JE, et al. (2009) Influence of cytokine gene variations on immunization to childhood vaccines. Vaccine 27: 6991-6997.
21. Pan L, Zhang W, Liang Z, Wu X, Zhu X, et al. (2012) Association between polymorphisms of the cytokine and cytokine receptor genes and immune response to hepatitis B vaccination in a Chinese Han population. J Med Virol 84: 26-33.
22. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, et al. (2000) Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31: 521-527.
23. Kimman TG, Vandebriel RJ, Hoebee B, (2007) Genetic variation in the response to vaccination. Community Genet 10: 201-217.
24. Milich DR, Leroux-Roels GG, (2003) Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2: 248-257.
25. Goncalves L, Albarran B, Salmen S, Borges L, Fields H, et al. (2004) The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20-28.
26. Portoles P, Rojo JM, (2009) The TCR/CD3 complex: opening the gate to successful vaccination. Curr Pharm Des 15: 3290-3300.
27. Janeway CA Jr, (1992) The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 10: 645-674.
28. Janeway CA Jr, Rojo J, Saizawa K, Dianzani U, Portoles P, et al. (1989) The co-receptor function of murine CD4. Immunol Rev 109: 77-92.
29. Cantrell DA, (2002) T-cell antigen receptor signal transduction. Immunology 105: 369-374.
30. Clevers H, Alarcon B, Wileman T, Terhorst C, (1988) The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6: 629-662.
31. Yudushkin IA, Vale RD, (2010) Imaging T-cell receptor activation reveals accumulation of tyrosine-phosphorylated CD3zeta in the endosomal compartment. Proc Natl Acad Sci U S A 107: 22128-22133.
32. Lenschow DJ, Walunas TL, Bluestone JA, (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.
33. Bretscher PA, (1999) A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 96: 185-190.
34. Sharpe AH, Freeman GJ, (2002) The B7-CD28 superfamily. Nat Rev Immunol 2: 116-126.
35. Harris NL, Ronchese F, (1999) The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 77: 304-311.
36. Alegre ML, Frauwirth KA, Thompson CB, (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1: 220-228.
37. Rogers PR, Croft M, (2000) CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J Immunol 164: 2955-2963.
38. Watts TH, (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
39. Croft M, So T, Duan W, Soroosh P, (2009) The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 229: 173-191.
40. De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, et al. (2009) The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 106: 5264-5269.
41. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, et al. (2008) Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 3: e1898.
42. Ryckman KK, Fielding K, Hill AV, Mendy M, Rayco-Solon P, et al. (2010) Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis. PLoS One 5: e12273.
43. Irving. BA, Weiss A, (1991) The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64: 891-901.
44. Lundholm M, Mayans S, Motta V, Lofgren-Burstrom A, Danska J, et al. (2010) Variation in the Cd3 zeta (Cd247) gene correlates with altered T cell activation and is associated with autoimmune diabetes. J Immunol 184: 5537-5544.
45. Aviles DH, Vehaskari MV, Culotta KS, Manning J, Ochoa AC, et al. (2009) T cell CD3 receptor zeta (TCRzeta)-chain expression in children with idiopathic nephrotic syndrome. Pediatr Nephrol 24: 769-773.
46. D'Oro U, Munitic I, Chacko G, Karpova T, McNally J, et al. (2002) Regulation of constitutive TCR internalization by the zeta-chain. J Immunol 169: 6269-6278.
47. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, et al. (2011) Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 7: e1002004.
48. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, et al. (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42: 426-429.
49. Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, et al. (2004) Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J Gastroenterol Hepatol 19: 1348-1356.
50. Geertsma MF, van Wengen-Stevenhagen A, van Dam EM, Risberg K, Kroon FP, et al. (1999) Decreased expression of zeta molecules by T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. J Infect Dis 180: 649-658.
51. Caballero B, (2007) The global epidemic of obesity: an overview. Epidemiol Rev 29: 1-5.
52. Huang IC, Frangakis C, Wu AW, (2006) The relationship of excess body weight and health-related quality of life: evidence from a population study in Taiwan. Int J Obes (Lond) 30: 1250-1259.
53. Poland GA, (1998) Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 15: 73-77.
54. Zuckerman JN, (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78: 169-177.
55. European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355: 561-565.
56. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI, (2007) Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82: 653-664.